previous studies employed either heating by a steamer or pressure cooking for antigen retrieval, we used a combination of pressure cooking and microwave heating. Second, we used a higher concentration of ZAP-70 antibody for immunohistochemistry; while we used 1:50, Sup et al., employed 1:200 and Carreras et al., employed 1:400 dilution. We speculate that these two factors contributed to a higher sensitivity of detection. The fact that we were able to detect a relatively low level of ZAP-70 expression in the germinal center B cells (other than the T cells), which were reported to be negative in the studies by Admirand et al., and Sup et al., supports this concept.
Receptor interleukin 3 (IL3) alpha-chain (Ra-IL3 or CD123) expression is described in approximately 80% of acute myeloid leukemias (AML) and may contribute to blast cell proliferative advantage, but the few T-acute lymphoblastic leukemias (T-ALL) reported were CD123 negative (reviewed in Testa et al. 1 ). T-ALLs represent expansions of cells arrested at various stages of lymphoid development. Several recent studies, using different approaches, suggested the existence of an immature (IM) T-ALL subtype. [2] [3] [4] [5] We defined this IM subtype by a surface T-cell receptor (TCR)/cytoplasmic TCRb negative phenotype. They represent 30% of adult and 15% of pediatric cases, are CD4/ 8DN, CD1aÀ, CD34 þ , with frequent expression of 'myeloid' markers (CD13, CD33, CD117) and distinct oncogenic lesions, predominantly CALM-AF10 and MLL. 5 They can be further classified on the basis of their TCRd, g and b gene configurations: IM0 demonstrates a germline configuration at all three loci; IMd demonstrates TCRd rearrangement; IMg T-ALLs, TCRd and TCRg rearrangements but no TCRb V(D)J and IMb T-ALLs have undergone TCRb VDJ. More mature T-ALLs can be identified by a sTCR-/cTCRb þ phenotype (defined as pre-ab) or a surface TCR. We demonstrated that in adult T-ALLs, o50% of IM cases enter complete remission (CR) after a single Correlation of ZAP-70 status and overall survival (Kaplan-Meier analysis). ZAP-70 low MCL patients survived significantly longer than ZAP-70 high MCL patients (P ¼ 0.03).
Letters to the Editor induction course, with 25% never achieving remission, compared to 490% of pre-ab cases. 6 IM cases may therefore benefit from novel induction regimens. Human IL3 targeted diphtheria toxin (DT) fusion proteins have been reported to be useful in CD123 þ AML. 7 We therefore evaluated CD123 expression in a series of 112 adult (415 years) and 107 pediatric T-ALL. CD123 expression was assessed in a single center by triple-color flow cytometry on fresh or dimethylsulfoxide cryoconserved samples. All T-ALLs included were CD7 þ , cytoplasmic and/or membrane CD3 þ , CD19À and MPOÀ. All 219 samples were evaluated for the CD13, CD33 and CD117 'myeloid markers' and only five (2%) demonstrated an European Group for the Immunological Characterization of Leukemias myeloid score 42, and of these, three expressed CD123 þ .
Overall, CD123 expression was found in 35/217 (16%) of T-ALLs, less frequently in pediatric (9/105, 9%) than adult cases (26/112, 23%). The level of CD123 expression was variable (ratios of fluorescence intensity (RFI) range 2.1-16; median 3.3) (Figure 1 ). CD123 expression was more common in IM T-ALLs, when it was found in 23/34 (68%) of adult IM0/d/g and 4/11 (36%) of pediatric IM0/d/g T-ALLs compared to only 5% of non-IM T-ALLs (Table 1) . To our knowledge, this is the first description of CD123 expression in a significant number of T-ALLs. CD123
þ AML exhibit a relatively immature phenotype with coexpression of CD117 and FLT3, higher cycling activity, increased resistance to apoptosis and poor prognosis.
8 Although limited numbers preclude definitive evaluation, it is noteworthy that among adult IM T-ALLs with known CD123 status included in the LALA94 study, 6 only 1/6 CD123 þ cases achieved CR after one course of induction, compared to 4/7 CD123À IM cases and two of the CD123 þ cases never achieved CR. These data suggest that within the subgroup of IM T-ALLs, CD123 expression should be tested prospectively as a simple, rapid method for identification of cases that could benefit from DT fused to variant human IL3 (DT-IL3) therapy. The feasibility of such an approach needs to be evaluated in a prospective setting. Relative fluorescent intensity of CD123 expression in representative T-ALLs. T-ALL blasts was classified as positive , using an anti-CD123-PE antibody (BD number 340545, clone 9F5), at CD123 RFI 42, based on the analysis of 48 AML controls, which demonstrated CD123 RFI 42 in 41/48 (85%) cases (data not shown), in line with previous reports. Lymphopoiesis of B-lineage cells is a complex process requiring stage-specific expression of multiple surface and cytoplasmic proteins that contribute to development and function. This complex process comprises biological progression from a lymphoid progenitor cell to a terminally differentiated plasma cell. Each step in this normal biological progression also has a malignant counterpart either referred to as leukemia or lymphoma (Figure 1a and b).
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The neutral endopeptidase 24.11, (NEP or CD10), is considered a regulator of B-cell growth and proliferation. 2 The enzyme is a cell surface aminopeptidase capable of degrading a number of bioactive peptides with various functions that depend on the cell type or tissue of origin and is active in early bone marrow (BM) precursor B cells and lymph node germinal center (GC) B cells. In addition, CD10 is expressed in malignancies including precursor B cell acute lymphocytic leukemia (B-ALL), GC-related non-Hodgkin's lymphoma (NHL) such as Burkitt's lymphoma and follicular lymphoma (FL), and GC-related diffuse large B-cell lymphomas (DLBCL). It is not, however, expressed in terminally differentiated plasma cells of multiple myeloma (MM), in the pre-GC cells of mantle cell lymphoma (MCL), or in the pre-or post-GC cells of B-cell chronic lymphocytic leukemia (B-CLL). Thus, there is a biphasic pattern of CD10 cell surface protein expression that correlates with specific stages of development in both normal and neoplastic B cells and precursor B cells (Figure 1c) .
The development of lymphoid malignancies involves the acquisition of a series of genetic and epigenetic alterations that give the cell a selective growth advantage. One cancer-related epigenetic alteration, gene promoter DNA methylation, occurs at cytosines within CG dinucleotides frequently clustered into cytosine-phosphate-guanosine (CpG) islands (reviewed by Laird 3 ). When CpG sites within a promoter CpG island are predominately methylated, there is frequently little or no expression of the associated gene. 4 Accumulating evidence indicates that abnormal DNA methylation of promoter and first 
